Emergent BioSolutions (EBS) Other Accumulated Expenses (2018 - 2026)

Emergent BioSolutions' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses fell 27.93% year-over-year to $8.0 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 27.93% decrease from a year earlier, with the FY2025 full-year figure at $10.8 million, down 50.68% from the prior year.
• Other Accumulated Expenses declined to $8.0 million in Q1 2026 per EBS's latest filing, from $10.8 million in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $67.6 million in Q3 2024 and bottomed at $8.0 million in Q1 2026.
• The 5-year median for Other Accumulated Expenses is $24.1 million (2025), against an average of $25.3 million.
• Across the five-year window, Other Accumulated Expenses tumbled 79.84% in 2022 and soared 76.96% in 2024, its largest moves.
• Year by year, Other Accumulated Expenses stood at $45.9 million in 2022, then fell by 28.76% to $32.7 million in 2023, then sank by 33.03% to $21.9 million in 2024, then tumbled by 50.68% to $10.8 million in 2025, then fell by 25.93% to $8.0 million in 2026.
• Per Business Quant, the three latest EBS Other Accumulated Expenses figures stand at $8.0 million (Q1 2026), $10.8 million (Q4 2025), and $24.1 million (Q3 2025).